10 October 2017
The European Commission has awarded 3.4 Million Euro under the Horizon 2020 programme to a new Marie Curie European Training Network - CARTNET, “Combatting Antimicrobial Resistance Training Network”, in which Oxford Drug Design is a consortium partner.
CARTNET brings together 13 academic and industrial research groups from 8 countries and will contribute to delivering solutions to the challenges of bacterial infectious diseases that affect both humans and animals.
This award is further recognition of the innovation that Oxford Drug Design is bringing to the search for new antibacterials. Oxford Drug Design will use its state-of-the-art drug discovery tools to optimizing existing inhibitors of the novel antibacterial target, histidine kinase, and the discovery of new ones. The ultimate aim is to develop antibacterial compounds with a good resistance profile as candidate novel antibiotics.
The project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 765147.
18 July 2017
Oxford Drug Design is pleased to announce the addition of Prof. David Livermore to our Scientific Advisory Board.
David Livermore gained his BSc in 1978 and his PhD in 1983. He worked at the London Hospital Medical College from 1980 until 1997 when he joined the Health Protection Agency (now Public Health England), becoming Director of its Antibiotic Resistance Monitoring and Reference Laboratory in 1998. In October 2011 he moved to become Professor of Medical Microbiology at the University of East Anglia but still retains sessions at Public Health England as its Lead on Antibiotic Resistance. He has broad interests on the mechanisms, evolution and dissemination of antibiotic resistance and its relationship to antibiotic usage. He sits on many i related to antibiotics and resistance and is a member of the UK Government's Antimicrobial Resistance & Healthcare Infections Advisory Committee. He publishes and speaks widely on resistance and has edited for several journals including Journal of Antimicrobial Chemotherapy, Journal of Medical Microbiology and International Journal of Antimicrobial Agents.
Outside of work he is a keen walker and, in 2016, completed a 3000-mile route that has taken him right around the perimeter of England.
29 June 2017
Oxford Drug Design is pleased to announce the appointment of James B. Kahn, M.D. FIDSA, to the company’s Scientific Advisory Board.
Dr. Kahn has deep and extensive knowledge of antibacterial drug development. He is Board-certified in both I.M. and I.D. After 18 years in the solo private practice of I.D. Medicine, James was recruited by Johnson & Johnson's Ortho-McNeil Pharmaceutical to be the first Director of their new I.D. Franchise. In addition to running numerous clinical trials for the antimicrobial FLOXIN, he also took over the clinical development of LEVAQUIN and was responsible for the sNDAs that led to 8 new FDA-approved indications. He proposed and then developed the higher-dose, shorter-course approach to accelerate pathogen eradication and reduce anti-bacterial exposure.
James is the founder and principal of JBK Strategic Consultations, LLC, a small firm providing Infectious Disease expertise to the Pharmaceutical, Venture Capital, and Medico-legal communities. He attends numerous national and international I.D. meetings and maintains close personal and professional contacts with many US and global opinion leaders.
10 May 2017
InhibOx has relaunched as Oxford Drug Design to reflect its transition to a biotechnology company focused on internal drug discovery. Our lead antibacterial programme has identified compounds with the potential to be developed into therapies for Gram-negative bacterial infections, including against strains resistant to multiple current antibacterial drug classes. In the European Union alone, drug-resistant bacteria are estimated to cause 25,000 deaths and cost more than $1.5 billion every year in healthcare expenses and productivity losses. Compound design is supported by a proprietary technology platform in cheminformatics, 3D molecular similarity and computer-aided drug design that has been built up over 10 years of research and development.
The potential of our programme has been validated by the award of a prestigious Innovate UK Biomedical Catalyst grant to accelerate programme progression.
1 April 2017
Oxford Drug Design has raised nearly $2m (£1.5m) of private investment to enable it to progress a novel antibacterial programme and continue to build its proprietary platform.
The funding, which will also help finance the company’s commercial and research and development (R&D) activities, was supported by both existing shareholders including IP Group plc as well as new investors including Busolantix Investment SA, O2h Ventures and a number of Business Angels.
Oxford Drug Design will continue to build and utilise its proprietary technology platform in cheminformatics, 3D molecular similarity and computer-aided drug design, in parallel with progressing the antibacterial programme.
1 March 2017
Oxford Drug Design (formerly InhibOx) has started work on a $1.1m (£900k) grant funded project to develop novel antibiotics. The project started four years ago as part of an EU-funded collaboration into multi-drug resistance. Capitalising on drug design, chemical synthesis and biology skills across the consortium, they have discovered new molecules with activity against a range of Gram-negative bacteria. The new money comes from Innovate UK, the UK's innovation agency, as part of the biomedical catalyst fund and will be used to design dual target inhibitors of aminoacyl tRNA synthetases for the treatment of multi-drug-resistant infections.
The compounds discovered so far inhibit a member of the tRNA synthetase family which plays a key role in protein biosynthesis. They have activity against a range of Gram-negative bacteria but need to be improved in terms of the level of activity and stability. This class of bacteria (which includes species such as E. coli and Klebsiella) has an extra layer to their cell wall. This provides them with an additional barrier to drug penetration, making them much harder to treat. By targeting more than one tRNA synthetase improvements should be seen in terms of both activity and decreased levels of bacterial resistance.
The next steps are to optimise the molecules to enhance their activity and stability and to monitor the emergence of resistance. The design work will be carried by over the next two years with the aim of developing a candidate ready for clinical testing.